Pacific Biosciences is reducing both headcount and spending across its DNA sequencing business, in the face of escalating global tariffs and threats to federal biomedical research grants. | Looking to ...

A major new initiative was launched on Tuesday (15 April) by the Wellcome Sanger Institute in collaboration with Pacific ...

US sequencing firm PacBio (Nasdaq: PACB) is cutting jobs and reducing spending across its business as it braces for the financial impact of new global tariffs and growing uncertainty around federal ...

Pacific Biosciences of California, Inc.’s PACB share price has dipped by 6.88%, which has investors questioning if this is ...

Pacific Biosciences of California (also known as PacBio) is pioneering long-read sequencing technology, which uses longer DNA segments to map the whole genome. Long-read sequencing can uncover ...

Detailed price information for Pacific Biosciences (PACB-Q) from The Globe and Mail including charting and trades.

A major new initiative, launched on 15 April, will map how gene activity shapes the immune system, and could help identify new therapeutic targets for conditions such as Inflammatory Bowel Disease ...

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve ... such as preparation kit to convert DNA into SMRTbell double-stranded DNA library ...